Medicus Pharma Ltd (MDCX)

$0.37 +0.02 (4.47%)
Market Cap 20.26M
Revenue (ttm) 0.00
Net Income (ttm) -35.46M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,968,500
Avg Vol 4,522,184
Day's Range N/A - N/A
Shares Out 56.66M
Stochastic %K 77%
Beta 0.14
Analysts Strong Sell
Price Target $5.67

Company Profile

Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus P...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 610 636 0184
Address:
300 Conshohocken State Road, Suite 200, West Conshohocken, United States
dzetu
dzetu Jun. 5 at 2:47 PM
$MDCX Increased my position again by 34k shares. Still optimistic, I see great potential. This is my second-largest holding after $CAPR.
0 · Reply
Krystalp9885
Krystalp9885 Jun. 5 at 2:25 PM
$MDCX
0 · Reply
ZTRADEZ_LLC
ZTRADEZ_LLC Jun. 5 at 1:41 PM
(NASDAQ: $MDCX )*Medicus Pharma Ltd (ON MY RADAR) MDCX is a clinical stage biotechnology company developing needle free treatments for skin cancer and other dermatology related conditions. Technical - Resting on a volume shelf and showing signs of a reversal. - Low-volume area ahead between $0.41 and $0.57. - Float sits below 10M shares. Fundamental • Advanced SkinJect into registrational development for Gorlin Syndrome, a rare genetic disorder associated with recurring skin cancers. • Secred up to $22 million in non dilutive financing to support clinical and regulatory milestones. • Phase 2 data demonstrated approximately 80% overall response rates, supporting continued advancement of its lead program. Full Read / Communicated Disclaimer https://www.ztradez.net/mdcx
0 · Reply
BullTradeFinder
BullTradeFinder Jun. 4 at 7:58 PM
$MDCX Move over .42 is a big spot. Holding 9 and 21 EMA on daily currently and looking good here for upside. Communicated-Disclaimer https://stockresearchtoday.com/mdcx/
0 · Reply
StockTrader2727
StockTrader2727 Jun. 4 at 7:54 PM
$MDCX people are missing this one
1 · Reply
jcooptechit
jcooptechit Jun. 4 at 5:44 PM
$MDCX MULTI-BILLION DOLLAR SKIN CANCER MARKET OPPORUNITY 🧬 Medicus Pharma advanced SkinJect into registrational development for Gorlin Syndrome which is a rare disease where patients can face hundreds of basal cell carcinomas over a lifetime. 🔹 FDA Phase 2b protocol submitted 🔹 Potential first lesion-directed therapy 🔹 Orphan Drug + Rare Pediatric Disease Voucher strategy 🔹 Encouraging Phase 2 clearance + safety data SkinJect could help reduce repeated surgeries while targeting a massive BCC / non-melanoma skin cancer market. 📌 Add MDCX to your watchlist. Communicated - Disclaimer: https://stockresearchtoday.com/mdcx/ Sector Peers: $BFRI $REPL $IDYA $MDWD
2 · Reply
The_Titan_Traders
The_Titan_Traders Jun. 4 at 3:33 PM
$MDCX Micro-cap biotech with a potentially disruptive skin cancer treatment platform and multiple clinical catalysts ahead. • Strong early clinical data has increased confidence in the lead program’s commercial potential and future regulatory progress. • Advancing toward additional FDA discussions and development milestones that could significantly increase visibility. • Multiple pipeline opportunities provide upside beyond a single asset. • With a small valuation and limited float, positive clinical or regulatory news could drive an outsized move higher. • High-risk, high-reward biotech setup where successful execution could lead to a substantial re-rating. COMMUNICATED-DISCLAIMER: https://stockresearchtoday.com/mdcx/
1 · Reply
JTE_Theta
JTE_Theta Jun. 4 at 2:28 PM
🚨 $MDCX - $22M non dilutive financing secured ! MDCX is a clinical stage biotech developing SkinJect, a patented microneedle patch that delivers chemotherapy directly to skin cancer lesions as a potential non invasive alternative to surgery. Why investors are paying attention: • SkinJect Phase 2 trial fully enrolled • Positive dose response trends in the lead cohort✅ • Phase 1 delivered complete responses with no dose limiting toxicities • Teverelix advancing in prostate cancer & acute urinary retention • FDA cleared Phase 2b study ✅ • Targeting a $6B combined market opportunity 🤖AI driven clinical development partnership 📈Multiple clinical & regulatory catalysts ahead Small cap biotech + multiple shots on goal + upcoming catalysts = one to watch ! CommunicatedDisclaimer:https://stockresearchtoday.com/mdcx/
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Jun. 4 at 1:34 PM
$MDCX : Tiny $18M Market Cap Targeting Multi Billion Dollar Markets!🚨 Medicus Pharma is quietly building a biotech pipeline focused on massive unmet markets in skin cancer and prostate/urology treatments through its proprietary SkinJect and Teverelix programs. Highlights: 🔥 Estimated cash runway now 24+ months 🔥 Positive Phase 2 SkinJect data showed registrational-grade clearance rates 🔥 FDA-cleared advancement for Teverelix Phase 2b study 🔥 Filed Orphan Drug application for SkinJect in Gorlin Syndrome Upcoming Catalysts: ✔️ More SkinJect clinical data ✔️ FDA/regulatory milestones ✔️ Potential partnerships/licensing deals ✔️ Teverelix Phase 2b progression Despite having a market cap of only around $18M, MDCX is pursuing potential multi billion dollar opportunities in markets projected to exceed $12B combined, including skin cancer, which impacts more than 5 million Americans each year. Communicated Disclaimer: http://stockresearchtoday.com/mdcx/ Sector peers: $CERO $MCRB $TCON $ABEO
0 · Reply
harrijakey
harrijakey Jun. 4 at 11:18 AM
$MDCX
0 · Reply
Latest News on MDCX
Medicus Pharma submits Protocol SKNJCT-005 to the FDA

2026-06-03T13:37:23.000Z - 2 days ago

Medicus Pharma submits Protocol SKNJCT-005 to the FDA

Medicus Pharma Advances SkinJect® into Registrational Development for Gorlin Syndrome

Jun 3, 2026, 8:00 AM EDT - 2 days ago

Medicus Pharma Advances SkinJect® into Registrational Development for Gorlin Syndrome

Medicus Pharma Announces $22 Million Non-Dilutive Financing

May 28, 2026, 8:00 AM EDT - 8 days ago

Medicus Pharma Announces $22 Million Non-Dilutive Financing

Medicus Pharma reports Q1 EPS (31c), consensus (22c)

2026-05-14T22:18:41.000Z - 21 days ago

Medicus Pharma reports Q1 EPS (31c), consensus (22c)

Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 14, 2026, 4:30 PM EDT - 21 days ago

Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

Medicus Pharma announces results from Phase 2 SKNJCT-003 analysis

2026-05-07T03:48:38.000Z - 4 weeks ago

Medicus Pharma announces results from Phase 2 SKNJCT-003 analysis

Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response

May 6, 2026, 7:30 AM EDT - 4 weeks ago

Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response

Medicus Pharma meets with lawmakers to support SkinJect designations

2026-04-27T13:31:02.000Z - 5 weeks ago

Medicus Pharma meets with lawmakers to support SkinJect designations

Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill

Apr 27, 2026, 7:30 AM EDT - 5 weeks ago

Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill

Medicus Pharma initiated with a Buy at Roth Capital

2026-04-21T11:53:55.000Z - 6 weeks ago

Medicus Pharma initiated with a Buy at Roth Capital

Medicus Pharma submits ODD application to U.S. FDA for SkinJect

2026-04-17T11:35:50.000Z - 7 weeks ago

Medicus Pharma submits ODD application to U.S. FDA for SkinJect

Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome

Apr 17, 2026, 7:30 AM EDT - 7 weeks ago

Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome

Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression

Apr 15, 2026, 7:30 AM EDT - 7 weeks ago

Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression

Medicus Pharma enters media partnership with New to The Street

2026-04-07T14:23:02.000Z - 2 months ago

Medicus Pharma enters media partnership with New to The Street

Medicus Pharma submits clinical study design to FDA for Teverelix

2026-04-06T11:37:11.000Z - 2 months ago

Medicus Pharma submits clinical study design to FDA for Teverelix

Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention

Apr 6, 2026, 7:30 AM EDT - 2 months ago

Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention

Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset

Apr 1, 2026, 7:30 AM EDT - 2 months ago

Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset

Medicus Pharma reports principal investigator validation of Phase 2 data

2026-03-30T13:38:08.000Z - 2 months ago

Medicus Pharma reports principal investigator validation of Phase 2 data

Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate

Mar 30, 2026, 7:30 AM EDT - 2 months ago

Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate

Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan

Mar 26, 2026, 7:30 AM EDT - 2 months ago

Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan

Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update

Mar 25, 2026, 4:30 PM EDT - 2 months ago

Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update

Medicus Pharma to discuss Skinject Phase 2 reults in fireside chat

2026-03-18T11:52:25.000Z - 2 months ago

Medicus Pharma to discuss Skinject Phase 2 reults in fireside chat

Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst

Mar 18, 2026, 7:30 AM EDT - 2 months ago

Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst

Medicus Pharma announces SkinJect Phase 2 KOL update

2026-03-16T11:50:31.000Z - 2 months ago

Medicus Pharma announces SkinJect Phase 2 KOL update

Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26

Mar 16, 2026, 7:30 AM EDT - 2 months ago

Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26

Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum

Mar 10, 2026, 7:30 AM EDT - 3 months ago

Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum

Medicus Pharma provides interpretation of Phase 2 SkinJect dataset

2026-03-09T11:40:33.000Z - 3 months ago

Medicus Pharma provides interpretation of Phase 2 SkinJect dataset

Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset

Mar 9, 2026, 7:30 AM EDT - 3 months ago

Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset

Medicus Pharma announces results from Phase 2 study of D-MNA

2026-03-05T13:10:22.000Z - 3 months ago

Medicus Pharma announces results from Phase 2 study of D-MNA

Medicus Pharma announces results from Phase 2 study of D-MNA

2026-03-05T12:35:46.000Z - 3 months ago

Medicus Pharma announces results from Phase 2 study of D-MNA

Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort

Mar 5, 2026, 7:30 AM EST - 3 months ago

Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort

Medicus Pharma To Participate in the 38th Annual Roth Conference

Mar 3, 2026, 7:30 AM EST - 3 months ago

Medicus Pharma To Participate in the 38th Annual Roth Conference

Medicus Pharma on Bloomberg World

Feb 12, 2026, 7:30 AM EST - 4 months ago

Medicus Pharma on Bloomberg World

Medicus signs six-part media series with New to the Street

2026-02-10T13:40:50.000Z - 4 months ago

Medicus signs six-part media series with New to the Street

Medicus receives FDA ‘study may proceed’ clearance for Teverelix Phase 2b study

2026-02-10T12:35:27.000Z - 4 months ago

Medicus receives FDA ‘study may proceed’ clearance for Teverelix Phase 2b study

Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk

Feb 10, 2026, 7:30 AM EST - 4 months ago

Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk

Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony

Jan 23, 2026, 7:30 AM EST - 4 months ago

Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony

Medicus announces amendment to LifeArc license improving Teverelix profile

2026-01-22T12:35:45.000Z - 4 months ago

Medicus announces amendment to LifeArc license improving Teverelix profile

Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile

Jan 22, 2026, 7:30 AM EST - 4 months ago

Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile

Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026

Jan 20, 2026, 7:30 AM EST - 4 months ago

Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026

Medicus Pharma announces clinical data on Teverelix

2026-01-12T12:50:08.000Z - 5 months ago

Medicus Pharma announces clinical data on Teverelix

Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women

Jan 12, 2026, 7:30 AM EST - 5 months ago

Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women

Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates

Jan 5, 2026, 7:30 AM EST - 5 months ago

Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates

Medicus Pharma enters non-binding LOI with Reliant AI

2025-12-22T12:46:17.000Z - 5 months ago

Medicus Pharma enters non-binding LOI with Reliant AI

Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform

Dec 22, 2025, 7:30 AM EST - 5 months ago

Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform

Medicus Pharma completes enrollment of 90 patients for Phase 2 study

2025-12-15T12:47:00.000Z - 6 months ago

Medicus Pharma completes enrollment of 90 patients for Phase 2 study

Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Dec 15, 2025, 7:30 AM EST - 6 months ago

Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement

Dec 5, 2025, 3:20 PM EST - 6 months ago

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement

Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President

Dec 1, 2025, 8:00 AM EST - 6 months ago

Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President

Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers

Nov 24, 2025, 8:00 AM EST - 6 months ago

Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers

Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Nov 17, 2025, 7:30 AM EST - 7 months ago

Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights

Nov 14, 2025, 5:00 PM EST - 7 months ago

Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights

Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Nov 13, 2025, 7:30 AM EST - 7 months ago

Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome

Oct 29, 2025, 7:30 AM EDT - 7 months ago

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome

Oct 29, 2025, 7:30 AM EDT - 7 months ago

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome

Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Oct 22, 2025, 7:30 AM EDT - 8 months ago

Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

The Vanderbilt Report: Medicus Pharma Ltd Built Three Separate Billion-Dollar Bets

Oct 14, 2025, 8:07 AM EDT - 8 months ago

The Vanderbilt Report: Medicus Pharma Ltd Built Three Separate Billion-Dollar Bets

Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025

Oct 13, 2025, 7:30 AM EDT - 8 months ago

Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025

Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE

Oct 7, 2025, 7:30 AM EDT - 8 months ago

Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE

Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject

Sep 29, 2025, 7:30 AM EDT - 8 months ago

Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject

Stonegate Capital Partners Initiates Coverage on Medicus Pharma Ltd. (MDCX)

Sep 24, 2025, 9:26 AM EDT - 9 months ago

Stonegate Capital Partners Initiates Coverage on Medicus Pharma Ltd. (MDCX)

Medicus Pharma Ltd. To Present at Brookline Capital Markets

Sep 24, 2025, 7:30 AM EDT - 9 months ago

Medicus Pharma Ltd. To Present at Brookline Capital Markets

Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing

Sep 18, 2025, 7:30 AM EDT - 9 months ago

Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing

Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Sep 8, 2025, 7:30 AM EDT - 9 months ago

Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Medicus Pharma Ltd. Completes Acquisition of Antev Limited

Sep 2, 2025, 7:30 AM EDT - 9 months ago

Medicus Pharma Ltd. Completes Acquisition of Antev Limited

Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial Highlights

Aug 21, 2025, 7:30 AM EDT - 10 months ago

Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial Highlights

Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines

Aug 4, 2025, 7:30 AM EDT - 10 months ago

Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines

Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders

Jul 23, 2025, 7:30 AM EDT - 11 months ago

Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders

Medicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025

Jul 21, 2025, 7:30 AM EDT - 11 months ago

Medicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025

Medicus Pharma Ltd. Announces Submission of Type C Meeting Request to the Food and Drug Administration (FDA)

Jul 8, 2025, 7:30 AM EDT - 11 months ago

Medicus Pharma Ltd. Announces Submission of Type C Meeting Request to the Food and Drug Administration (FDA)

dzetu
dzetu Jun. 5 at 2:47 PM
$MDCX Increased my position again by 34k shares. Still optimistic, I see great potential. This is my second-largest holding after $CAPR.
0 · Reply
Krystalp9885
Krystalp9885 Jun. 5 at 2:25 PM
$MDCX
0 · Reply
ZTRADEZ_LLC
ZTRADEZ_LLC Jun. 5 at 1:41 PM
(NASDAQ: $MDCX )*Medicus Pharma Ltd (ON MY RADAR) MDCX is a clinical stage biotechnology company developing needle free treatments for skin cancer and other dermatology related conditions. Technical - Resting on a volume shelf and showing signs of a reversal. - Low-volume area ahead between $0.41 and $0.57. - Float sits below 10M shares. Fundamental • Advanced SkinJect into registrational development for Gorlin Syndrome, a rare genetic disorder associated with recurring skin cancers. • Secred up to $22 million in non dilutive financing to support clinical and regulatory milestones. • Phase 2 data demonstrated approximately 80% overall response rates, supporting continued advancement of its lead program. Full Read / Communicated Disclaimer https://www.ztradez.net/mdcx
0 · Reply
BullTradeFinder
BullTradeFinder Jun. 4 at 7:58 PM
$MDCX Move over .42 is a big spot. Holding 9 and 21 EMA on daily currently and looking good here for upside. Communicated-Disclaimer https://stockresearchtoday.com/mdcx/
0 · Reply
StockTrader2727
StockTrader2727 Jun. 4 at 7:54 PM
$MDCX people are missing this one
1 · Reply
jcooptechit
jcooptechit Jun. 4 at 5:44 PM
$MDCX MULTI-BILLION DOLLAR SKIN CANCER MARKET OPPORUNITY 🧬 Medicus Pharma advanced SkinJect into registrational development for Gorlin Syndrome which is a rare disease where patients can face hundreds of basal cell carcinomas over a lifetime. 🔹 FDA Phase 2b protocol submitted 🔹 Potential first lesion-directed therapy 🔹 Orphan Drug + Rare Pediatric Disease Voucher strategy 🔹 Encouraging Phase 2 clearance + safety data SkinJect could help reduce repeated surgeries while targeting a massive BCC / non-melanoma skin cancer market. 📌 Add MDCX to your watchlist. Communicated - Disclaimer: https://stockresearchtoday.com/mdcx/ Sector Peers: $BFRI $REPL $IDYA $MDWD
2 · Reply
The_Titan_Traders
The_Titan_Traders Jun. 4 at 3:33 PM
$MDCX Micro-cap biotech with a potentially disruptive skin cancer treatment platform and multiple clinical catalysts ahead. • Strong early clinical data has increased confidence in the lead program’s commercial potential and future regulatory progress. • Advancing toward additional FDA discussions and development milestones that could significantly increase visibility. • Multiple pipeline opportunities provide upside beyond a single asset. • With a small valuation and limited float, positive clinical or regulatory news could drive an outsized move higher. • High-risk, high-reward biotech setup where successful execution could lead to a substantial re-rating. COMMUNICATED-DISCLAIMER: https://stockresearchtoday.com/mdcx/
1 · Reply
JTE_Theta
JTE_Theta Jun. 4 at 2:28 PM
🚨 $MDCX - $22M non dilutive financing secured ! MDCX is a clinical stage biotech developing SkinJect, a patented microneedle patch that delivers chemotherapy directly to skin cancer lesions as a potential non invasive alternative to surgery. Why investors are paying attention: • SkinJect Phase 2 trial fully enrolled • Positive dose response trends in the lead cohort✅ • Phase 1 delivered complete responses with no dose limiting toxicities • Teverelix advancing in prostate cancer & acute urinary retention • FDA cleared Phase 2b study ✅ • Targeting a $6B combined market opportunity 🤖AI driven clinical development partnership 📈Multiple clinical & regulatory catalysts ahead Small cap biotech + multiple shots on goal + upcoming catalysts = one to watch ! CommunicatedDisclaimer:https://stockresearchtoday.com/mdcx/
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Jun. 4 at 1:34 PM
$MDCX : Tiny $18M Market Cap Targeting Multi Billion Dollar Markets!🚨 Medicus Pharma is quietly building a biotech pipeline focused on massive unmet markets in skin cancer and prostate/urology treatments through its proprietary SkinJect and Teverelix programs. Highlights: 🔥 Estimated cash runway now 24+ months 🔥 Positive Phase 2 SkinJect data showed registrational-grade clearance rates 🔥 FDA-cleared advancement for Teverelix Phase 2b study 🔥 Filed Orphan Drug application for SkinJect in Gorlin Syndrome Upcoming Catalysts: ✔️ More SkinJect clinical data ✔️ FDA/regulatory milestones ✔️ Potential partnerships/licensing deals ✔️ Teverelix Phase 2b progression Despite having a market cap of only around $18M, MDCX is pursuing potential multi billion dollar opportunities in markets projected to exceed $12B combined, including skin cancer, which impacts more than 5 million Americans each year. Communicated Disclaimer: http://stockresearchtoday.com/mdcx/ Sector peers: $CERO $MCRB $TCON $ABEO
0 · Reply
harrijakey
harrijakey Jun. 4 at 11:18 AM
$MDCX
0 · Reply
supplySHOCK
supplySHOCK Jun. 4 at 8:56 AM
$AEVA $MDCX $IMSR $BTGO mee
0 · Reply
woodruffn2
woodruffn2 Jun. 3 at 8:14 PM
$MDCX lets go
0 · Reply
stocks_2watch
stocks_2watch Jun. 3 at 5:40 PM
$MDCX, Medicus Pharma Advances SkinJect®️ into Registrational Development for Gorlin Syndrome: https://medicuspharma.com/medicus-pharma-advances-skinject-into-registrational-development-for-gorlin-syndrome/
0 · Reply
bullrider19
bullrider19 Jun. 3 at 3:50 PM
$MDCX BUY BUY 11500 BIG BIG BULL$$$$$$$$$$$$$$$$$$
0 · Reply
ozell
ozell Jun. 3 at 3:14 PM
$MDCX Why do a forward split and dilute shareholders why not just buy up the float? Once float is bought up share price will rise. In my opinion is the better move
2 · Reply
Joshuastride
Joshuastride Jun. 3 at 3:12 PM
$MDCX let’s go
0 · Reply
luminouslumens
luminouslumens Jun. 3 at 3:09 PM
$ADTX $MDCX $AIIO $GNS
1 · Reply
Moneyindabanknow
Moneyindabanknow Jun. 3 at 3:07 PM
$MDCX Time to fly!!!
0 · Reply
ZoomZoomMoney
ZoomZoomMoney Jun. 3 at 2:22 PM
$MDCX
0 · Reply
Moneyindabanknow
Moneyindabanknow Jun. 3 at 2:19 PM
$MDCX This could really squeeze guys.
0 · Reply
Moneyindabanknow
Moneyindabanknow Jun. 3 at 2:11 PM
$MDCX this is gonna be an absolute gaint
0 · Reply
Moneyindabanknow
Moneyindabanknow Jun. 3 at 2:05 PM
$MDCX .50 than $ land real quick
0 · Reply